Which scenario illustrates a permissible 503A compounding?

• A. Compounding a liquid medication for an infant when the commercially available medication is only a tablet
• B. Compounding a medication that has a commercially available equivalent in the marketplace
• C. Compounding a medication with the same dye as the available product for patient convenience
• D. Compounding a product for office use on a routine basis without a patient prescription

Answer: (A)

Under 503A, compounding is allowed when it is for a specific patient based on a valid prescription and meets a patient’s individual needs that aren’t met by commercially available products—such as creating a dosage form or strength tailored to that patient.

In this scenario, an infant requires a liquid formulation, but the only commercially available form is a tablet. Crafting a liquid dosage to accommodate an infant’s dosing and administration is a legitimate patient-specific formulation, so it fits 503A criteria.

The other situations don’t meet those conditions. Making a product that already has a marketed equivalent is generally not allowed under 503A unless there’s a documented shortage or a genuine patient-specific reason not addressed by the available product. Using the same dye as the marketed product solely for convenience would amount to duplicating a branded product without a therapeutic need, which isn’t the intended use of pharmacy compounding. Finally, producing a product for office use on a routine basis without a patient prescription isn’t allowed under 503A, which requires an individualized prescription for each compounded preparation.